Patents​

• “Methods and assays for identifying compounds that modulate proteinprotein interactions.” P.S. Wright, P. Weissensee, H. Eishingdrelo, and J. Cai, Sanofi, US Patent # 8574865 (11/13)

• “Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(Trans-1,4diaminocyclohexyl)-purines and their use as antiproliferative agents.” D. Borcherding, J.A. Dumont, N.P. Peet, and P.S. Wright, Aventis Pharmaceuticals Inc., US Patent # 7429595 (9/08)

• “Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(Trans-1,4diaminocyclohexyl)-purines and their use as antiproliferative agents.” D. Borcherding, J.A. Dumont, N.P. Peet, and P.S. Wright, Aventis Pharmaceuticals Inc., US Patent # 6861524 (3/05)

• “Alkyl-4-silylheterocyclic phenols and thiophenol useful as antioxidant agents.” R.A. Parker, M.L. Edwards, M.J. Vaal, J.E. Matt, K.S. Chen, M.T. Yates, P.S. Wright, and S.J. Busch, Hoechst Marion Roussel, US Patent # 6121463 (9/00)

• “Substituted Phenols and Thiophenols useful as antioxidant agents.” R.A. Parker, P.S. Wright, S.J. Busch, K.S. Chen, and M.T. Yates, Hoechst Marion Roussel, US Patent # 6114572 (9/00)

• “Novel indole derivatives useful in down-regulating estrogen receptor regulation.”  A.J. Bitonti, E.T. Jarvi, I.A. McDonald, F.G. Salituro, J. Whitten, and P.S. Wright,  Merrell Dow Pharm. Inc.  US Patent # 5877202 (3/99)

• “Method of inhibiting vascular cell adhesion molecule-1 and treating inflammatory disease with 2,6-di-alkyl-4-silyl-phenols.”  P.S. Wright and S.J. Busch, Merrell Dow Pharm. Inc., US Patent #5,795,876  (8/98)

•  “Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents.”  R. Parker, M. Edwards, M. Vaal, K. Chen, M. Yates, P.S. Wright, and S.J. Busch, Merrell Dow Pharm., Inc., US Patent # 5,608,095 (3/97)

• “Antiangiogenic Oligomers”  P.S. Wright and A.J. Bitonti,  Merrell Dow Pharm. Inc., US Patent # 5,593,664 (1/97)
   

Selected Publications

• “High-content phenotypic screening and triaging strategy to identify small molecules driving oligodendrocyte progenitor cell differentiation.” J.V. Peppard, C.A. Rugg, M.A. Smicker, E. Powers, E. Harnish, J. Prisco, D. Cirovic, P.S. Wright, P.R. August, and K.J. Chandross (2015) J Biomol. Screening 20, 382-390.

• “Compound screening platform using human induced pluripotent stem cells to identify molecules that promote chondrogenesis.” S-L Yang, E. Harnish, T. Leeuw, U. Dietz, E. Batchelder, P.S. Wright, J. Peppard, P. August, C. VolleChallier, F. Bono, J-M Herbert, and J.C.I. Belmonte (2012) Protein Cell  3(12), 934-942.

• “Intracellular Insulin-like Growth Factor-1 Induces Bcl-2 Expression in Airway Epithelial Cells.” H.S. Chand, J.F. Harris, Y. Mebratu, Y. Chen, P.S. Wright, S.H. Randell, and Y. Tesfaigzi (2012) J. Immunol. 188, 4581-4589.

• “A Cell-Based Protein-Protein Interaction Method Using a Permuted Luciferase Reporter.”  H. Eishingdrelo, J. Cai, P. Weissensee, P. Sharma, M.J. Tocci and P.S. Wright (2011) Curr. Chem Genomics 5, 122-128.

• “Human T helper (Th) cell lineage commitment is not directly linked to the secretion of IFN-g or IL-4: Characterization of Th cells isolated by FACS based on IFN-g and IL-4 secretion” W. Cao, Y. Chen, S. Alkan, A. Subramaniam, F. Long, H. Liu, R. Diao, T. Delohery, J. McCormick, R. Chen, D. Ni, P.S. Wright, X. Zhang, S. Busch, and A. Zilberstein (2005) Eur. J. Immunol. 35, 2709-2717.

• “Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids” C. Richard, D. Matthews, W. Duivenvoorden, J. Yau, P.S. Wright, and J.P.H. Th’ng (2005) Clin. Cancer Res. 11, 3523-3529.

• “Comparing gene discovery from Affymetrix GeneChip microarrays and Clontech PCR-select cDNA subtraction: a case study”  W. Cao, C. Epstein, H. Liu, C. DeLoughery, N. Ge, J. Lin, R. Diao, H. Cao, F. Long, X. Zhang, Y. Chen, P.S. Wright, S. Busch, M. Wenck, K. Wong, A.G. Saltzman, Z. Tang, L. Liu, and A. Zilberstein. (2004) BMC Genomics 5(1); 26.

• “SPRR1B overexpression enhances entry of cells into the G0 phase of the cell cycle.” Y. Tesfaigzi, P.S. Wright, and S.A. Belinsky (2003) Am. J. Physiol. Lung Cell Mol Physiol. 285, L889-L898.

• “Expression of p21Waf1/Cip1 and Cyclin D1 is increased in butyrate-resistant HeLa cells”  A. Derjuga, C. Richards, M. Crosato, P.S. Wright, L. Chalifour, J. Valdez, A. Barraso, H.A. Crissman, W. Nishioka, E.M. Bradbury, and J.P.H. Th’ng (2001) J. Biol. Chem 276, 37815-37820.

• “The design and synthesis of purine inhibitors of CDK-2. Part 3.”  P.W. Shum, N.P. Peet, P.M. Weintraub, T.B. Le, Z. Zhao, F. Barbone, B. Cashman, J. Tsay, S. Dwyer, P.C. Loos, E.A. Powers, K. Kropp, P.S. Wright, A. Bitonti, J. Dumont, and D.R. Borcherding (2001) Nucleosides and Nucleotides 20 (4-7), 1067-1078.

•  “Crystal structure of human cyclin dependent kinase 2 in complex with the adenine derived inhibitor H717”  M.K. Dreyer, D. Borcherding, J.A. Dumont, N.P. Peet, J.T. Tsay, P.S. Wright, A.J. Bitonti, and S.-H. Kim (2001) J. Med Chem 44, 524-530.

•  “Induction of vascular cell adhesion molecule-1 expression by IL-4 in human aortic smooth muscle cells is not associated with increased nuclear NF-κB levels”  P.S. Wright, J.R. Cooper, K.E. Kropp, and S.J. Busch (1999) J. Cell Phys.  180, 381-389.

• “Microautoradiographic quantitation of vascular endothelial growth factor mRNA levels in human prostate specimens containing normal and neoplastic epithelium” R.D. Woessner, P.S. Wright, D.E. Loudy, C.D. Wallace, L.R. Montgomery, and B.R. Nestok  (1998)  Exp. Mol. Pathol. 65, 37-52.

• “Clomiphene analogs with activity in vitro and in vivo against human breast cancer cells”  R.J. Baumann, T.L. Bush, D.E. Cross-Doersen, E.A. Cashman, P.S. Wright, J.H. Zwolshen, G.F. Davis, D.P. Mathews, D.M. Bender, and A.J. Bitonti (1998) Biochem. Pharm. 55, 841-851.

•  “Decreased vascular endothelial growth factor expression associated with tumor regression induced by MDL 101,731”  R.D. Woessner, T.L. Bush, M.T. Lewis, D.E. Cross-Doersen, A.J. Bitonti, N. Prakash, L.R. Montgomery, D.E. Loudy, and P.S. Wright  (1997) Oncology Res. 9, 543-552.

• “Quantitation of vascular endothelial growth factor mRNA levels in human breast tumors and metastatic lymph nodes”  P.S. Wright, D.E. Loudy, D.E. CrossDoersen, L.R. Montgomery, J. Sprinkle-Cavallo, J.A. Miller, C.M. Distler, E.E. Lower, and R.D. Woessner (1997) Exp. Mol. Pathol. 64, 41-51.

• “Cyclic AMP regulation of mouse proline-rich protein gene expression: Isoproterenol induction of AP-1 transcription factors in parotid glands”  J. Zhou, P.S. Wright, E. Wong, K. Jessen, J.N. Morand, and D.M. Carlson Arch. Biocem. Biophys. (1997) Arch. Biochem. Biophys. 338, 97-103.

• “Depletion of estrogen receptor in human breast tumor cells by a novel substituted indole that does not bind to the hormone binding domain”  A.J. Bitonti, J.A. Dumont, F.G. Salituro, I.A. McDonald, E.T. Jarvi, L.M. Frey, P.S. Wright, and R.J. Baumann (1996) J. Steroid Biochem. Mol. Biol. 58, 21-30.

• “A small proline-rich protein, SPRR1, is upregulated early during tobacco smokeinduced squamous metaplasia in rat nasal epithelia”  J. Tesfaigzi, J. Th’ng, J.A. Hotchkiss, J.R. Harkema, and P.S. Wright (1996) Am. J. Resp. Cell Mol. Biol. 14, 478-486.

• “A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and TRPM-2 mRNA levels in human prostate tumor xenografts”  P.S. Wright, D.E. Cross-Doersen, J.P.H. Th’ng, X.-W. Guo, H.A. Crissman, E.M. Bradbury, L.R. Montgomery, F.Y. Thompson, D.E. Loudy, J.O. Johnston, and A.J. Bitonti (1996) Exp.Cell Res. 222, 54-60.

• “Regulation of ornithine decarboxylase mRNA levels in human breast cancer cells: Pattern of expression and involvement of core enhancer promoter element”  P.S. Wright, J.R. Cooper, D.E. Cross-Doersen, J.A. Miller, P.A. Chmielewski, R.L. Wagner, K.A. Streng, and M.A. Flanagan (1995) Cell Growth Differ. 6, 1097-1102.

• “Measurement of mRNA levels in tissue sections with quantitative autoradiography and in situ hybridization”  P.S. Wright, D. E. Cross-Doersen, P.A. Chmielewski, T.L. Bush, A.J. Bitonti, and J.A. Miller (1995) FASEB J. 9, 279-283.

•  “Regression of human breast tumor xenografts in response to (E)-2’-deoxy-2’(fluoromethylene)cytidine, an inhibitor of ribonucleotide diphosphate reductase”  A.J. Bitonti, T.L. Bush, J.A. Dumont, E.A. Cashman, D.E. Cross-Doersen, P.S. Wright, D.P. Matthews, J.R. McCarthy and D.A. Kaplan (1994) Cancer Res. 54, 1485-1490.

• “A small proline-rich protein regulated by vitamin A in tracheal epithelial cells is induced in lung tumors”  J.Tesfaigzi, P.S. Wright, V. Oreffo, G. An, R. Wu, and D.M. Carlson (1993) Am. J. Resp. Cell Mol. Biol. 9, 434-440.

• “An echistatin c-terminal peptide activates GPIIbIIIa binding to fibrinogen, fibronectin, vitronectin, and collagen type I and type IV.”  P.S. Wright, V. Saudek, T.J. Owen, S.L. Harbeson, and A.J. Bitonti (1993) Biochem. J. 293, 263-267.

• “Inhibition of angiogenesis in vitro and in ovo with an inhibitor of cellular protein kinases, MDL 27032.”  P.S.Wright, Cross-Doersen, D., Miller, J.A., Jones, W.D., and Bitonti, A.J. (1992) J. Cell. Phys. 152, 448-457.

• “Molecular Structure and Transcriptional Regulation of the Salivary Gland Proline-Rich Protein Multigene Families.” D.M. Carlson, J. Zhou, and P.S. Wright  (1991) Prog. Nucl. Acids Res. Mol. Biol. 41, 1-22.

• “Disruption of Plasmodium falciparum-infected erythrocyte cytoadherence to human melanoma cells with inhibitors of glycoprotein processing. P.S.Wright, D.E. Cross- Doersen, K.K. Schroeder, T.L. Bowlin, P.P. McCann, and A.J. Bitonti.”(1991) Biochem. Pharmacol. 41, 1855-1861.

• “Irreversible inhibition of S-adenosylmethionine decarboxylase in Plasmodium falciparum-infected erythrocytes: Growth inhibition in vitro.”  P.S. Wright, T.L.

• Byers, D.E. Cross-Doersen, P.P. McCann, and A.J. Bitonti (1991) Biochem. Pharmacol. 41, 1713-1718.

• “The FT210 cell line is a G2 phase mutant with a temperature sensitive CDC2 gene product.”  J.P.H. Th’ng, P.S. Wright, J. Hamaguchi, M.G. Lee, C.J. Norbury, P. Nurse, and E.M. Bradbury (1990) Cell 63, 313-324.

• “Plasmodium falciparum: A Rapid Assay for Cytoadherence of [3H]-Hypoxanthine-Labelled Infected Erythrocytes to Human Melanoma Cells.”  P.S. Wright, D.E. Cross-Doersen, P.P. McCann, and A.J. Bitonti (1990) Exp. Parasit. 71, 346-349.

• “Regulation of Proline-Rich Protein Gene Expression by Cyclic AMP in Primary Cultures of Hamster Parotid Glands.”  P.S. Wright, C. Lenney, and D.M. Carlson (1990) J. Mol. Endocrinol. 4, 81-87.

• “Regulation of Proline-Rich Protein and α-Amylase Genes in Parotid-Hepatoma Hybrid Cells.”  P.S. Wright and D.M. Carlson (1988) FASEB J. 2, 3104-3107.

• “Proline-Rich Proteins: Products of Tissue-Specific Multigene Families.”  D.K. Ann, P.S. Wright, and D.M. Carlson (1988) in Altered Glycosylation in Tumor Cells ed. D.D. Khalsa, New York, N.Y., Alan R. Liss, Inc., pp. 213-216.

• “Butyrate Effects on Normal and Resistant Hepatoma Cells: Morphological Response and Implications for Vectoral Cholesterol Transport.”  P.S. Wright, D.T. Dudley, and R. Chalkley (1986) Arch. Biochem. Biophys. 248, 243-252.

• “Chinese Hamster Ovary Cells Depend on Exogenous Lipids to Survive Phospholipase C Treatment.”  P.S. Wright and C. Kent (1986) Arch. Biochem. Biophys. 245, 104-113.

• “The Regulation of Phosphatidylcholine Biosynthesis in Chinese Hamster Ovary Cells by Reversible Membrane Association of CTP:phosphocholine Cytidylyltransferase.”  P.S. Wright, J.N. Morand, and C. Kent (1985) J. Biol. Chem. 260, 7919-7926.

• “A Functional Membrane Repair System in Duchenne’s Muscular Dystrophy.”  P.S. Wright, E. McKinney, S. Berry, A. Evers, and C. Kent (1984) J. Neurol. Sci. 64, 259-264.